IRB #

STUDY00015495

Title

A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)

Principal Investigator

Gina Vaccaro

Study Purpose

To compare the effectiveness of Pembrolizumab (study drug) compared to
standard of care therapies in adults with Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Carcinoma

Medical Condition(s)

Microsatellite Instability-High (MSI-H) stage IV Colorectal Cancer
Mismatch Repair Deficient (dMMR) stage IV Colorectal Cancer

Eligibility Criteria

1. Male or female age 18 or older
2. Confirmed MMR deficient (dMMR) or microsatellite instability high (MSI-H) stage IV colorectal carcinoma
3. No prior systemic therapy for stage IV colorectal cancer


Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Treatment will continue until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment. After that participants will be contacted by phone every 3 months until the end of the study.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
knight@ohsu.edu

Sponsor

Merck Sharp & Dohme Corp.

Recruitment End

12/31/2030

Compensation Provided

No


Go Back